Research Grants
May 2002 . November 2002 . May 2003 . November 2003 . May 2004 . May 2005 . November 2005 . May 2006 . November 2006 . May 2007 . November 2007 . November 2008
2nd Grant Competition - November, 2002
OICR's Grants and Awards Program continues to attract much interest in the Ontario cancer research community. The Cancer Research Fund received 74 Registration of Intents and 57 full submissions. In total, approximately $8.7 million was awarded to 19 projects in both clinical and translational research, representing a success rate of 33 per cent.
| Principal Investigator | Institution | Project Type/Title | Award* |
| Attisano, Liliana | University of Toronto | Translational: Identification of small molecule inhibitors of the Wnt pathway | $532,800 |
| Barr, Ronald | McMaster University | Companion: An economic evaluation of the treatment of acute lymphoblastic leukemia in childhood | $664,650 |
| Ben-David, Yaacov | Sunnybrook and Women's College Health Sciences Centre | Translational: The role of Cox-2 inhibition in the treatment of leukemia and lymphoma | $483,498 |
| Bouffet, Eric | Hospital for Sick Children | Clinical: A phase II study of vinblastine sulphate injection in children with current or refractory low grade glioma | $304,970 |
| Bristow, Robert G. | University Health Network | Translational: Pre-clinical efficacy and biomaker analyses pertaining to a novel DNA repair inhibitor in prostrate and pancreatic cancer | $487,296 |
| Chan, Helen | Hospital for Sick Children | Clinical: Phase II study of high dose chemotherapy with cyclosporine for vision-threatening intraocular retinoblastoma | $551,723 |
| Feilotter, Harriet E. | Queen's University | Translational: Multi-dimensional profiling of follicular lymphoma | $360,176 |
| Gallie, Brenda L. | University Health Network | Companion: Comparative effectiveness of conventional and informatics-assisted clinical management and clinical trial participation | $446,066 |
| Gallinger, Steven | Mount Sinai Hospital | Companion: Improving care and research in pancreas cancer in Ontario - a population-based study | $446,232 |
| Gariepy, Jean | University Health Network | Translational: Design and mining of single chain toxin libraries to find anti-breast cancer agents | $387,792 |
| Kim, John | University Health Network | Clinical: Phase I/II Trial of celecoxib with preoperative chemoradiation for respectable rectal cancer with in vivo analysis of celecoxib effector pathways | $330,034 |
| Klotz, Laurence | Sunnybrook and Women's College Health Sciences Centre | Companion: Effect of intermittent versus continuous androgen suppression on bone loss and body composition in a phase III randomized trial | $540,000 |
| Liu, Fei-Fei | University Health Network | Translational: Innovative gene therapy approaches for nasopharyngeal carcinoma | $501,478 |
| Mackillop, William | Queen's University | Companion: Translating the results of clinical trials of radiochemotherapy into improved health outcomes in the general population | $848,644 |
| Pace-Asciak, Cecil | Hospital for Sick Children | Translational: Novel anti-leukemic compounds - in vivo translation | $602,136 |
| Pignol, Jean-Philippe | Sunnybrook and Women's College Health Sciences Centre | Translational: An intermediate photon energy tomotherapy unit (IPET) for cancer treatment | $265,626 |
| Rutka, James Thomas | Hospital for Sick Children | Translational: Gli2 as a target for the treatment of medulloblastoma | $531,914 |
| Smith, Andrew J. | Sunnybrook and Women's College Health Sciences Centre | Clinical: Improving colon cancer staging through a multimodal knowledge translation program aimed at surgeons and pathologists | $246,633 |
| Wright, James | Hamilton Regional Cancer Centre | Companion: Identifying patients for clinical trials participation - the value of systematic screening | $159,600 |
* Includes a value of 20 per cent added for institution overhead.